BriaCell Therapeutics Corp.
BCTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001610820
No open-market purchases or sales by BriaCell Therapeutics Corp. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $1.58M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in BriaCell Therapeutics Corp. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −1 vs. Q3 2021
- Shares held
- 1.32M
- +728.3K (+123.5%) vs. Q3 2021
- Total value
- $10.9M
- +$6.14M (+128.7%) vs. Q3 2021
- New holders
- 7
- 8 more added
- Sold out
- 8
- 3 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $1.58M |
| Q1 2026 | 16 | $1.62M |
| Q4 2025 | 13 | $69.2K |
| Q3 2025 | 13 | $136.5K |
| Q2 2025 | 16 | $181.1K |
| Q1 2025 | 14 | $94.1K |
| Q4 2024 | 26 | $379.1K |
| Q3 2024 | 22 | $538.1K |
| Q2 2024 | 20 | $452.0K |
| Q1 2024 | 20 | $6.38M |
| Q4 2023 | 26 | $14.6M |
| Q3 2023 | 21 | $17.0M |
| Q2 2023 | 21 | $17.9M |
| Q1 2023 | 21 | $19.4M |
| Q4 2022 | 21 | $12.3M |
| Q3 2022 | 22 | $14.3M |
| Q2 2022 | 22 | $17.0M |
| Q1 2022 | 18 | $33.5M |
| Q4 2021 | 20 | $10.9M |
| Q3 2021 | 21 | $4.77M |
| Q2 2021 | 24 | $20.3M |
| Q1 2021 | 10 | $1.45M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding BriaCell Therapeutics Corp.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Toronto Dominion Bank | 39 | $0 | 0.00% | +36+1,200.0% | Added |
| Advisor Group Holdings, Inc. | 12 | $0 | 0.00% | 00.0% | Unchanged |
| Captrust Financial Advisors | 420 | $3.00K | 0.00% | +270+180.0% | Added |
| Royal Bank of Canada | 283 | $3.00K | 0.00% | +283 | New |
| Koshinski Asset Management, Inc. | 500 | $4.14K | 0.00% | +500 | New |
| UBS Group AG | 1,402 | $12.0K | 0.00% | −1,675−54.4% | Reduced |
| Simplex Trading, LLC | 2,669 | $22.0K | 0.00% | +2,669 | New |
| Tower Research Capital LLC (TRC) | 4,545 | $38.0K | 0.00% | +642+16.4% | Added |
| Morgan Stanley | 8,297 | $68.0K | 0.00% | +1,036+14.3% | Added |
| Concord Wealth Partners | 12,775 | $106.0K | 0.03% | +12,775 | New |
| Total Clarity Wealth Management, Inc. | 15,818 | $131.0K | 0.06% | +4,393+38.5% | Added |
| Eqis Capital Management, Inc. | 16,174 | $134.0K | 0.01% | −475−2.9% | Reduced |
| Insight Advisors, LLC | 16,900 | $140.0K | 0.04% | +16,900 | New |
| Apollon Wealth Management, LLC | 22,900 | $190.0K | 0.02% | +3,500+18.0% | Added |
| Virtu Financial LLC | 24,977 | $207.0K | 0.02% | −7,975−24.2% | Reduced |
| National Bank of Canada | 29,900 | $248.0K | 0.00% | +29,900 | New |
| Summit Trail Advisors, LLC | 35,000 | $290.0K | 0.02% | 00.0% | Unchanged |
| Redmond Asset Management, LLC | 137,098 | $1.14M | 0.32% | +505+0.4% | Added |
| Voloridge Investment Management, LLC | 203,366 | $1.68M | 0.01% | +46,420+29.6% | Added |
| Lynwood Capital Management Inc. | 785,000 | $6.50M | 6.22% | +785,000 | New |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −62,139−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −40,302−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −35,232−100.0% | Sold out |
| Belvedere Trading LLC | 0 | $0 | 0.00% | −13,608−100.0% | Sold out |
| Gofen & Glossberg LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −4,687−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −372−100.0% | Sold out |
| Harbour Investments, Inc. | 0 | $0 | 0.00% | −110−100.0% | Sold out |